Sage Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SAGE Nasdaq 2836 www.sagerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sage Therapeutics, Inc.

Sage Therapeutics price target lowered to $8 from $9 at Wedbush - Oct 10th, 2024 12:46 pm
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study - Oct 9th, 2024 4:26 pm
Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment - Oct 8th, 2024 2:53 pm
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study - Oct 8th, 2024 1:19 pm
Sage continues downslide as Alzheimer’s study fails - Oct 8th, 2024 12:21 pm
Sage Therapeutics stock drops after disappointing Alzheimer's trial results - Oct 8th, 2024 11:06 am
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Oct 8th, 2024 10:30 am
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why - Oct 7th, 2024 4:27 pm
Sector Update: Health Care Stocks Steady Late Afternoon - Oct 4th, 2024 7:59 pm
Sector Update: Health Care Stocks Softer Friday Afternoon - Oct 4th, 2024 5:58 pm
Sage stock slides as RBC cuts rating to Sell on trial results concerns - Oct 4th, 2024 1:14 pm
Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now - Sep 29th, 2024 11:54 am
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 - Sep 27th, 2024 2:27 pm
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends - Sep 27th, 2024 11:28 am
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - Sep 26th, 2024 2:37 pm
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program - Sep 26th, 2024 11:00 am
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers - Sep 25th, 2024 3:34 pm
Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound? - Aug 30th, 2024 3:31 pm
Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report - Aug 3rd, 2024 12:40 pm
Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations - Aug 2nd, 2024 11:26 am